Epizyme News Headlines (NASDAQ:EPZM)

$11.06
-0.09 (-0.81 %)
(As of 09/23/2019 01:30 AM ET)
Today's Range
$10.85
Now: $11.06
$11.31
50-Day Range
$11.12
MA: $12.59
$13.94
52-Week Range
$5.14
Now: $11.06
$16.59
Volume819,286 shs
Average Volume699,608 shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.46

Headlines

Epizyme (NASDAQ EPZM) News Headlines

Source:
DateHeadline
Epizyme Inc (NASDAQ:EPZM) Expected to Announce Earnings of -$0.54 Per ShareEpizyme Inc (NASDAQ:EPZM) Expected to Announce Earnings of -$0.54 Per Share
www.americanbankingnews.com - September 21 at 8:07 PM
Epizyme Inc (NASDAQ:EPZM) Receives Average Rating of "Buy" from AnalystsEpizyme Inc (NASDAQ:EPZM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 12 at 5:38 PM
Epizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue? - Yahoo FinanceEpizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
finance.yahoo.com - September 8 at 11:08 AM
Epizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue?Epizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - September 8 at 11:08 AM
Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth - Yahoo FinanceEpizyme Announces Board of Director Appointments to Support Continued Evolution and Growth - Yahoo Finance
finance.yahoo.com - September 5 at 1:57 PM
Where Will Epizyme Be in 1 Year? - Motley FoolWhere Will Epizyme Be in 1 Year? - Motley Fool
www.fool.com - September 5 at 1:57 PM
Fulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs Team - Yahoo FinanceFulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs Team - Yahoo Finance
finance.yahoo.com - September 4 at 10:26 AM
Epizyme (EPZM) Announces Grant Bogle and Victoria Richon, Ph.D to Board; Beth Seidenberg, MD to Step Down - StreetInsider.comEpizyme (EPZM) Announces Grant Bogle and Victoria Richon, Ph.D to Board; Beth Seidenberg, MD to Step Down - StreetInsider.com
www.streetinsider.com - September 4 at 10:26 AM
Epizyme Announces Board of Director Appointments to Support Continued Evolution and GrowthEpizyme Announces Board of Director Appointments to Support Continued Evolution and Growth
finance.yahoo.com - September 4 at 10:26 AM
$5.50 Million in Sales Expected for Epizyme Inc (NASDAQ:EPZM) This Quarter$5.50 Million in Sales Expected for Epizyme Inc (NASDAQ:EPZM) This Quarter
www.americanbankingnews.com - August 31 at 1:17 AM
Epizyme to Participate in Upcoming September Conferences - Yahoo FinanceEpizyme to Participate in Upcoming September Conferences - Yahoo Finance
finance.yahoo.com - August 30 at 7:58 PM
Epizyme to Participate in Upcoming September ConferencesEpizyme to Participate in Upcoming September Conferences
finance.yahoo.com - August 29 at 11:41 AM
How Should Investors Feel About Epizyme, Inc.s (NASDAQ:EPZM) CEO Pay? - Yahoo FinanceHow Should Investors Feel About Epizyme, Inc.'s (NASDAQ:EPZM) CEO Pay? - Yahoo Finance
finance.yahoo.com - August 16 at 7:55 PM
How Should Investors Feel About Epizyme, Inc.'s (NASDAQ:EPZM) CEO Pay?How Should Investors Feel About Epizyme, Inc.'s (NASDAQ:EPZM) CEO Pay?
finance.yahoo.com - August 16 at 7:55 PM
Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat - Yahoo FinanceEpizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat - Yahoo Finance
finance.yahoo.com - August 15 at 11:44 AM
Epizymes NDA Filing Acceptance Moves It Forward Toward New Territory - Seeking AlphaEpizyme's NDA Filing Acceptance Moves It Forward Toward New Territory - Seeking Alpha
seekingalpha.com - August 13 at 1:23 AM
Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates - Yahoo FinanceEpizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates - Yahoo Finance
finance.yahoo.com - August 12 at 12:35 PM
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo FinanceEpizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
finance.yahoo.com - August 10 at 11:18 AM
Horizon Therapeutics (HZNP) Q2 Earnings Beat Estimates - Yahoo FinanceHorizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates - Yahoo Finance
finance.yahoo.com - August 9 at 8:05 AM
Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2 - NasdaqImmunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2 - Nasdaq
www.nasdaq.com - August 9 at 8:05 AM
Catalysts (CPRX) Q2 Earnings and Revenues Beat Estimates - NasdaqCatalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates - Nasdaq
www.nasdaq.com - August 9 at 8:05 AM
Form 10-Q Epizyme, Inc. For: Jun 30 - StreetInsider.comForm 10-Q Epizyme, Inc. For: Jun 30 - StreetInsider.com
www.streetinsider.com - August 9 at 8:05 AM
Epizyme Reports Business Progress and Second Quarter 2019 Results - Yahoo FinanceEpizyme Reports Business Progress and Second Quarter 2019 Results - Yahoo Finance
finance.yahoo.com - August 9 at 8:05 AM
Epizyme Reports Business Progress and Second Quarter 2019 ResultsEpizyme Reports Business Progress and Second Quarter 2019 Results
finance.yahoo.com - August 9 at 8:05 AM
Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference - Yahoo FinanceEpizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference - Yahoo Finance
finance.yahoo.com - August 6 at 10:26 AM
Epizyme to Present at the Wedbush PacGrow 2019 Healthcare ConferenceEpizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference
finance.yahoo.com - August 6 at 10:26 AM
Unum Therapeutics Announces New Appointments to its Board of Directors - Yahoo FinanceUnum Therapeutics Announces New Appointments to its Board of Directors - Yahoo Finance
finance.yahoo.com - July 29 at 11:30 PM
Unum Therapeutics Announces New Appointments to its Board of Directors - GlobeNewswireUnum Therapeutics Announces New Appointments to its Board of Directors - GlobeNewswire
www.globenewswire.com - July 29 at 12:12 PM
Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for - Yahoo FinanceAnalysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
finance.yahoo.com - July 26 at 1:06 AM
Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma - Yahoo FinanceEpizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma - Yahoo Finance
finance.yahoo.com - July 26 at 1:06 AM
Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - July 26 at 1:06 AM
Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid SarcomaEpizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma
finance.yahoo.com - July 25 at 6:34 AM
New finance chief at Epizyme - Seeking AlphaNew finance chief at Epizyme - Seeking Alpha
seekingalpha.com - July 22 at 9:06 AM
Epizyme: A Promising Long-Term Pick For The Healthcare Investor - Seeking AlphaEpizyme: A Promising Long-Term Pick For The Healthcare Investor - Seeking Alpha
seekingalpha.com - July 20 at 10:01 AM
Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors - GlobeNewswireFate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors - GlobeNewswire
www.globenewswire.com - July 17 at 6:09 PM
How being a female tech founder prepared this CEO to fight the medical system when she got cancer - CNBCHow being a female tech founder prepared this CEO to fight the medical system when she got cancer - CNBC
www.cnbc.com - July 13 at 5:23 PM
Heres Why Epizyme Rose 103.7% in the First Half of 2019 - The Motley FoolHere's Why Epizyme Rose 103.7% in the First Half of 2019 - The Motley Fool
www.fool.com - July 13 at 5:23 PM
Here's Why Epizyme Rose 103.7% in the First Half of 2019Here's Why Epizyme Rose 103.7% in the First Half of 2019
finance.yahoo.com - July 12 at 6:29 PM
Epizyme Announces Positive Interim Data on Lead Candidate - Yahoo FinanceEpizyme Announces Positive Interim Data on Lead Candidate - Yahoo Finance
finance.yahoo.com - June 25 at 11:16 AM
Updated Epizyme data from tazemetostat Phase 2 trial positive - Seeking AlphaUpdated Epizyme data from tazemetostat Phase 2 trial 'positive' - Seeking Alpha
seekingalpha.com - June 21 at 6:57 PM
Epizyme (EPZM) Announces Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory FL - StreetInsider.comEpizyme (EPZM) Announces Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory FL - StreetInsider.com
www.streetinsider.com - June 21 at 11:08 AM
Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular LymphomaEpizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma
finance.yahoo.com - June 21 at 11:08 AM
Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data - Yahoo FinanceEpizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data - Yahoo Finance
finance.yahoo.com - June 12 at 11:25 AM
Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report? - NasdaqWhy Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report? - Nasdaq
www.nasdaq.com - June 6 at 6:36 PM
Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report? - Yahoo FinanceWhy Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report? - Yahoo Finance
finance.yahoo.com - June 5 at 6:36 PM
Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?
finance.yahoo.com - June 5 at 6:36 PM
Epizyme (EPZM) Presents Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at ASCO 2019 Meetings - StreetInsider.comEpizyme (EPZM) Presents Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at ASCO 2019 Meetings - StreetInsider.com
www.streetinsider.com - June 3 at 8:45 AM
Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual MeetingEpizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting
finance.yahoo.com - June 3 at 8:45 AM
Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition - Boston Business JournalAhead of cancer conference, Epizyme CEO talks first drug, Regeneron competition - Boston Business Journal
www.bizjournals.com - June 1 at 8:52 AM
Epizymes NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure - Yahoo FinanceEpizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure - Yahoo Finance
finance.yahoo.com - May 31 at 6:32 PM
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Featured Article: Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel